NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
78.83 +0.45 (+0.57%) GOLD FUTURES
2,322.50 -1.70 (-0.07%) DOW
38,988.82 +104.56 (+0.27%) Bitcoin GBP
50,023.28 -750.43 (-1.48%)
Travere Therapeutics, Inc. (TVTX)
- Simply Wall St.
Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at Travere Therapeutics...
- GuruFocus.com
Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
Discover how Travere Therapeutics Inc (TVTX) achieved a robust revenue increase and navigated regulatory landscapes in the first quarter of 2024.
- GlobeNewswire
Travere Therapeutics Reports First Quarter 2024 Financial Results
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511 new patient start forms (PSFs) for FILSPARI in Q1 2024; Total of 1,963 PSFs received since launch Net product sales of FILSPARI totaled $19.8 million for the first quarter of 2024 European Commission recently granted conditional marketing authorization (CMA) to FILSPARI for the treatment
